Precision or personalized medicine is currently gaining a lot of attention. Clinical evidence for its effectiveness has been established based on randomized clinical trials accounting for classical risk factors, such as hypertension, diabetes, and serum lipids. However, besides such classical risk factors, the genetic background should be considered, at least for heritable traits, including atherosclerotic cardiovascular disease (ASCVD). Such classical risk factors are almost always incidents that have already occurred in which it may be too late to start treatment, instead of indicators of presymptomatic state. Human genome information is associated with most traits, including ASCVD. Two methods of implementing precision medicine for ASCVD using human genome information are currently being investigated: the use of rare genetic variations that have large effect sizes and polygenic risk scores that are composed of multiple common genetic variations. This review article emphasizes the importance of clinical as well as genetic diagnoses when implementing precision medicine. Precision medicine should be considered based on comprehensive genetic analyses, encompassing rare to common genetic variations.

Key words: Precision medicine, Genetics, Cholesterol
Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome⁶. Subsequently, an international collaborative effort worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage, which was completed in 2004⁷. After the initial report of the entire human genome, millions of individuals have had their whole genomes sequenced. It is estimated that single nucleotide variations (SNVs) occur 1 in 1000 base pairs, on average, although they do not occur at a uniform density. Therefore, we are quite similar to one another: we are all, regardless of race, 99.9% identical genetically. Because of this similarity, it is sometimes quite difficult to identify the causative mutation or mutations associated with a disease. Conversely, “heritability” is a concept that describes the degree in which a certain trait can be attributed to a genetic variation.

Heritability has been estimated from so-called twin studies. We can estimate heritability by comparing a trait in monozygotic twins and dizygotic twins. Serum lipids as well as ASCVD have been shown to be highly heritable traits, with a heritability of approximately 60%⁸,⁹ (Fig. 1). Because of this high heritability, precision medicine for serum lipids and ASCVD based on the human genome should be quite useful.

**FH as the Primary Model of Precision Medicine for ASCVD**

If we have a chance to see only a single patient with homozygous FH who has double loss-of-function mutations in the LDL receptor or its associated gene, it is quite easy to understand the causal relationship between LDL cholesterol and ASCVD¹⁰. Probands who have double deleterious mutations have percutaneous and tendon xanthomas associated with extremely high LDL cholesterol, almost always leading to premature cardiac death, whereas their unaffected relatives do not exhibit such complications¹¹. Those of their relatives who have a single mutation, i.e., patients with heterozygous FH, exhibit the exact middle phenotype³. These observations in general show that a deleterious mutation in the LDL receptor is the cause of this condition. The prevalence of this condition in the general population had been considered as approximately 1 in 500 cases¹². However, we found a prevalence of homozygous FH of 1 in 208 cases in the Hokuriku district of Japan in 2011¹³. Following this report, other groups have found similar prevalence in the United States and Europe¹⁴,¹⁵ (Fig. 2). Accordingly, identifying and
treating FH are now considered public health problems. Additionally, there are a substantial number of studies that suggested that early intervention in patients with homozygous FH in this region. Similarly, the prevalence of heterozygous FH in estimated to be around 1 in 217 cases and that in the US to be around 1 in 250 cases. Reproduced with permission from Mabuchi, et al. Atherosclerosis, 2011; 214: 404-407.

The prevalence of heterozygous FH in the Hokuriku area in Japan is estimated to be around 1 in 208 cases, according to the number of patients with homozygous FH in this region. Similarly, the prevalence of heterozygous FH in estimated to be around 1 in 217 cases and that in the US to be around 1 in 250 cases. Reproduced with permission from Mabuchi, et al. Atherosclerosis, 2011; 214: 404-407.

![Prevalence of FH : From experience of > 2,000 cases](image)

**Fig. 2.** Prevalence of heterozygous familial hypercholesterolemia (FH) in Hokuriku, Japan

The prevalence of heterozygous FH in the Hokuriku area in Japan is estimated to be around 1 in 208 cases, according to the number of patients with homozygous FH in this region. Similarly, the prevalence of heterozygous FH in estimated to be around 1 in 217 cases and that in the US to be around 1 in 250 cases. Reproduced with permission from Mabuchi, et al. Atherosclerosis, 2011; 214: 404-407.

![Pie chart showing frequency of Homozygous Heterozygous and Normal FH](image)

**Fig. 3.** Impact of cascade screening on the prognosis of familial hypercholesterolemia (FH)

Reproduced with permission from Tada, et al. J Am Coll Cardiol, 2020; 75(11 Supplement 1): 1921.
Genetic Diagnosis of FH: Is it Necessary, and Why?

An essential question for clinicians caring for FH patients is whether genetic testing for FH is necessary or useful. Genetic testing is fundamental for the diagnosis because FH is a genetic disorder; some experts said that clinical diagnostic criteria are sufficient. However, there are several important reasons for conducting genetic testing for FH:

• Genetic testing is useful in cases in which the clinical diagnosis is unclear. This is true for many patients because family structure is changing, leading to uncertainty regarding family history information.

• Genetic testing can differentiate between heterozygous and homozygous FH. Although the LDL cholesterol phenotypes of normal individuals, individuals heterozygous for FH, and individuals homozygous for FH show a trimodal distribution, there is a substantial overlap between heterozygous and homozygous FH. We typically classify these cases as “severe FH.” However, genetic testing can diagnose homozygous FH accurately so that patients homozygous for FH can be treated by special medications, including microsomal triglyceride transfer protein inhibitors, angioptietin-like protein 3 (ANGPTL3) inhibitor, and LDL apheresis. Accurate diagnosis through genetic testing should be quite important among homozygous FH because such treatments are usually expensive. Note that as of September 2020, ANGPTL3 inhibitor is not still officially approved to use for the patients of homozygous FH in Japan.

• Genetic testing can differentiate other phenocopies, such as sitosterolemia, autosomal recessive hypercholesterolemia (ARH), and cerebrotendinous xanthomatosis. Differential diagnosis of these conditions is critically important because the optimal treatment strategy is different for different diagnoses.

• Genetic testing is also useful for the detection of double heterozygotes with LDL receptor and its related genes.

• The genetic status of FH is associated with ASCVD beyond LDL cholesterol level; thus, the determination of genetic status can be used as a biomarker for ASCVD. Based on these, genetic testing for FH is useful. Currently, several types of panel sequencing covering known FH genes have been developed, and the cost of sequencing has been gradually reduced over the years. We are now conducting a randomized, waiting list-controlled, open-label study to see if genetic testing and disclosure of the results will lead to a better prognosis.

• Some patients with FH have additional rare mutations associated with LDL cholesterol elevation. We have called this condition oligogenic FH; these patients have significantly higher LDL cholesterol levels than patients with pure monogenic FH (Fig. 4).

Precision Medicine for FH

As already stated, FH can be diagnosed very early by cascade screening and universal screening. Accumulated evidence suggests that LDL cholesterol-lowering therapy may not need to be so intensive in patients who are diagnosed and start treatment at an early phase. In our experience, a homozygous FH patient whose LDL cholesterol level was not adequately lowered but who started treatment at 13 years of age had a better prognosis than his older brother, with nearly the same genetic and environmental background, who started his treatment at 23 years of age. The patients’ genetic status can help us to determine how and when to treat them. If a patient with FH has an ATP-binding cassette subfamily G member 5/8 (ABCG5/ABCG8) rare mutation besides an LDL receptor mutation, ezetimibe should be added to statin treatment, since there is a report that showed that dyslipidemic patients with a mutation in the ABCG5/ABCG8 gene exhibited better response when adding ezetimibe on top of atorvastatin therapy (Fig. 5). Imaging modalities, such as carotid ultrasound and coronary computed tomography (CT), as well as physiological function tests, such as pulse wave velocity, have been shown to be useful for further risk stratification.

Precision Medicine for ASCVD in the General Population

As stated above, genetic testing for FH, assuming this condition is caused by a rare genetic mutation or mutations appears to lead to precision medicine for ASCVD. How about ASCVD in the general population? The risk of ASCVD is highly heritable among the general population. To determine the “hidden” biomarkers of ASCVD, a number of genetic association studies have identified many loci and common genetic variations associated with inherited elevation in the risk of ASCVD. Although a single common genetic variation does not have enough power to be used in precision medicine, combining multiple common genetic variations into a single score has been shown to be clinically useful for this purpose,
initial score could show a significant association with the events, it did not add useful information in terms of risk discrimination. A few years later, we showed that a polygenic risk score using 50 SNVs was associated with ASCVD outcomes. The initial attempt was published in 2010, where a polygenic risk score based on 13 SNVs associated with ASCVD was moderately associated with actual ASCVD events. Although this

Fig. 4. Impact of genetic status of familial hypercholesterolemia (FH) and oligogenic FH
Compared with individuals with mutation-negative FH who are potentially affected by polygenic causes, individuals with monogenic FH have higher low-density lipoprotein (LDL) cholesterol and higher odds for coronary artery disease (CAD). Additionally, those with oligogenic FH appear to have even higher LDL cholesterol and higher odds for CAD. Reproduced with permission from Tada, et al. Curr Opin Lipidol, 2019; 30: 300-306.

Fig. 5. Personalized medicine for hyper-low-density lipoprotein (LDL) cholesterolemia according to mutation status of the ABCG5/ABCG8 gene
Vertical arrows indicate the degree of LDL cholesterol reduction when adding ezetimibe on top of atorvastatin 10 mg. Individuals who have an ABCG5 or ABCG8 genetic mutation have a better response to the addition of ezetimibe to atorvastatin treatment. Reproduced with permission from Tada, et al. Lipids Health Dis, 2020; 19: 3.

including ASCVD outcomes. The initial attempt was published in 2010, where a polygenic risk score based on 13 SNVs associated withASCVD was moderately associated with actual ASCVD events. Although this
significantly associated with ASCVD events, beyond family history information, and that it was as useful as other traditional risk factors for risk discrimination. Furthermore, a polygenic risk score that comprised approximately 6.6 million SNVs appears to be much more powerful. Interestingly, when we look at extreme phenotypes, such as early onset of myocardial infarction (<55 years), the contribution of such polygenic high risk appears to be much higher than that of FH caused by rare mutations. Now that we know how to pinpoint a set of individuals at high risk, we should know how to lower their risk. There are two simple established ways to do this. The first is statin therapy. It has been shown that statin therapy is much more effective in patients with polygenic high risk than in those with polygenic low risk. The results clearly suggest that statin therapy can reduce at least a portion of the high risk for ASCVD. The second is healthy lifestyle. Another study showed that a healthy lifestyle can reduce polygenic high risk. Thus, DNA is not destiny; it is not deterministic of this disease. We can find other ways of lowering the risk if we have more data. Furthermore, there are different lifestyles in different parts of the world. Currently, most data come from groups investigating people of European ancestry. We have to find other strategies using data from people of other ethnicities.

Phenome in Addition to Genome

Recently, so-called phenome-wide association studies (PheWAS) have become feasible based on the increased availability of phenotypic data from electronic health records. These studies can better characterize human genome–phenome relationships. Particularly, PheWAS has the advantage of identifying genetic variants with pleiotropic properties, either good or bad. Cai et al. showed that individuals with a particular SNV in the interleukin 6 receptor gene (IL6R) were at reduced risk for aortic aneurysms, besides known “on-target” effect of IL6R blockade from clinical trials (reduced risk of coronary heart disease) as well as “off-target” effect (higher hemoglobin level). Rao et al. showed that a PCSK9 missense variant was associated with a reduced risk of ischemic stroke and was not associated with an increased risk of diabetes. These results appear to be compatible with findings obtained in clinical trials using PCSK9 inhibitors. Furthermore, a recent PheWAS focusing on Lipoprotein (a) [Lp(a)] genotypes and thousands of phenotypes showed an inverse relationship between FH and elevated Lp(a). Lp(a) is elevated in patients with FH, the mechanism of which remains unclear. This study clearly showed that Lp(a) levels were elevated in patients with a clinical diagnosis of FH, based on a higher frequency of LPA genotypes leading to elevated LDL cholesterol, premature cardiovascular disease, and family history of cardiovascular disease, thereby increasing the likelihood of being diagnosed with FH.

Future Directions

As stated repeatedly, precision medicine for ASCVD based on human genome information is quite reasonable, and it is the way to go. We need several items and steps to pursue this goal:

- We need much more data regarding the human genome and ASCVD. The human genome, as well as environmental factors, is quite diverse across ethnicities. Thus, we need data from ethnicities globally to feel confident.
- We need more advanced genotyping technology. Although so-called next-generation sequencing has facilitated our research over the decades, it still requires several steps that consume time and effort, such as polymerase chain reaction (PCR). If we can determine DNA sequences without PCR, the time and cost of DNA sequencing will be dramatically reduced.
- We need a good educational program for the general public to accept such advanced technology. It is sometimes quite difficult to explain to people why genotyping is important. As stated above, DNA is not destiny, at least for ASCVD development. There are several simple ways to ease the risk of ASCVD. Appropriate recognition of precision medicine based on the human genome among the general population is a prerequisite for this goal.
- We need randomized, controlled trials of intervention with statins and/or healthy lifestyle based on genotype to show the benefits of precision medicine.

Conclusion

We have repeatedly emphasized that precision medicine for ASCVD based on the human genome is already feasible. However, several more steps are required for it to be accepted as a common practice.

Acknowledgements and Notice of Grant Support

This paper was presented at the 52nd Annual Scientific Meeting of the Japan Atherosclerosis Society.

Conflict of Interest Disclosures

None.
hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011; 214: 404-407

14) Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J, 2016; 37: 1384-1394

15) de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation, 2016; 133: 1067-1072

16) Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, Yamashita T, Miyamoto Y, Yamamoto A, Tomoihe H, Yokoyama S. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2010; 17: 667-674

17) Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg-HN, Masana L, Descamps O, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman H, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Brickert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-90a

18) Luirink IK, Wiegman A, Kusters DM, Hof MH, Grootenberg HN, de Groot E, Kastelein JJP, Hutten BA. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolaemia. N Engl J Med, 2019; 381: 1547-1556

19) Brandts J, Ray KK. LDL-Cholesterol Lowering Strategies and Population Health - Time to Move to a Cumulative Exposure Model. Circulation, 2020; 141: 873-876

20) Ademi Z, Watts GF, Pang J, Sijbrands EJ, van Bockxmeer HW, Dusault-Wijkstra JE, Williams M, Roeters van Lennep J. Cascade screening of familial hypercholesterolemia must go on. Atherosclerosis, 2015; 242: 415-417

21) Besseling J, Sjouke B, Kastelein JJ. Screening and treatment of familial hypercholesterolaemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). Atherosclerosis, 2015; 241: 597-606

22) van Maarle MC, Stouthard ME, Bonsel GJ. Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet, 2003; 40: e3

23) Tada H, Okada H, Nomura A, Nohara A, Yamagishi M, Takamura M, Kawashiri MA. Determining Impact of Cascade Screening for Familial Hypercholesterolemia on Cardiovascular Events. J Am Coll Cardiol, 2020; 75(11 Supplement 1): 1921

24) Groselj U, Kovac J, Sustar U, Mlinaric M, Fras Z, Podkrajsek KT, Battelino T. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis, 2018; 277: 383-391

25) McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolemia in the UK: A cost-utility analysis. Atherosclerosis, 2018; 275: 434-443

26) Bowman FL, Molster CM, Lister KJ, Bauskis AT, Garton-Smith J, Vickery AW, Watts GF, Martin AC. Identifying Perceptions and Preferences of the General Public Concerning Universal Screening of Children for Familial Hypercholesterolaemia. Public Health Genomics, 2019; 22: 25-35

27) Tada H, Hosomichi K, Okada H, Kawashiri MA, Nohara A, Inazu A, Tomizawa S, Tajima A, Mabuchi H, Hayashi K. A de novo mutation of the LDL receptor gene as the cause of familial hypercholesterolemia identified using whole exome sequencing. Clin Chim Acta, 2016; 453: 194-196

28) Tada H, Inaba S, Pozharitckaia D, Kawashiri MA. Promising Tools for the Identification of Early Manifestations of Familial Hypercholesterolemia in Japan. Intern Med, 2018; 57: 1119-1122

29) Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, Baum SJ, Catapano AL, Chapman MJ, Defesche JC, Folco E, Freiberger T, Genest J, Hovingh GK, Harada-Shiba M, Humphries SE, Jackson AS, Mata P, Moriarty PM, Raa FJ, Al-Rasadi K, Ray KK, Reiner Z, Sijbrands EJ, Yamashita S; International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Defining severe familial hypercholesterolemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol, 2016; 4: 850-861

30) Nohara A, Otsuho Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, Jurecka A. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGI-I Long-Term Extension Study. J Atheroscler Thromb, 2019; 26: 368-377

31) Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, Chyu KY, Sasiela WJ, Chan KC, Brisson D, Khoury E, Banerjee P, Gusarova V, Gromada J, Stahl N, Yancopoulos GD, Hovingh GK. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med, 2017; 377: 296-297

32) Tada H, Nohara A, Inazu A, et al. Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. J Atheroscler Thromb, 2018; 25: 783-789

33) Tada H, Kawashiri MA, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M. Autosomal recessive hypercholesterolemia: a mild phenotype of familial hypercholesterolemia - insight from the kinetic study using stable isotope and animal studies. J Atheroscler Thromb, 2015; 22: 1-9

34) Tada H, Inaba S, Pozharitckia D, Kawashiri MA. Prominent Tendon Xanthomas and Abdominal Aortic Aneurysm Associated with Cerebrotendinous Xanthomatosis Identified Using Whole Exome Sequencing. Intern Med, 2018; 57: 1119-1122

35) Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J, 2017; 38: 1573-1579
36) Tada H, Kawashiri MA, Nomura A, Teramoto R, Hosomichi K, Nohara A, Inazu A, Mabuchi H, Tajima A, Yamagishi M. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol, 2018; 12: 1436-1444

37) Nomura A, Tada H, Okada H, Nohara A, Ishikawa H, Yoshimura K, Kawashiri MA. Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol. BMJ Open, 2018; 8: e023636

38) Tada H, Okada H, Nomura A, Yashiro S, Nohara A, Ishigaki Y, Takamura M, Kawashiri MA. Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype. Circ J, 2019; 83: 1917-1924

39) Tada H, Usui S, Sakata K, Takamura M, Kawashiri MA. Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology. J Atheroscler Thromb, 2020; 27: 489-498

40) Tada H, Okada H, Nomura A, Takamura M, Kawashiri MA. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis, 2020; 19: 3

41) Tada H, Kawashiri MA, Okada H, Teramoto R, Konno T, Yoshimuta T, Sakata K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M, Hayashi K. Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. Am J Cardiol, 2015; 115: 724-729

42) Tada H, Kawashiri MA, Okada H, Nakahashi T, Sakata K, Nohara A, Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia. Am J Cardiol, 2017; 120: 1955-1960

43) Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Assessment of arterial stiffness in patients with familial hypercholesterolemia. J Clin Lipidol, 2018; 12: 397-402

44) Tada H, Kawashiri MA. Genetic Variations, Triglycerides, and Atherosclerotic Disease. J Atheroscler Thromb, 2019; 26: 128-131

45) Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O, Salomaa V, Peltonen L, Kathiresan S. A multic locus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet, 2010 Oct 23; 376(9750): 1393-1400

46) Tada H, Melander O, Louie JZ, Catanese JJ, Rowland CM, Devlin JJ, Kathiresan S, Shiffman D. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur Heart J, 2016; 37: 561-567

47) Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet, 2018; 50: 1219-1224

48) Khera AV, Chaffin M, Zekavat SM, Collins RL, Roselli C, Natarajan P, Lichtman JH, D’Onofrio G, Mattera J, Dreyer R, Spertus JA, Taylor KD, Psaty BM, Rich SS, Post W, Gupta N, Lander E, Ida Chen YD, Talkowski ME, Rotter JI, Kathiresan S. Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. Circulation, 2019; 139: 1593-1602

49) Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet, 2015; 385: 2264-2271

50) Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, Fuster V, Boerwinkle E, Melander O, Ridker PM, Kathiresan S. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med, 2016; 375: 2349-2358

51) Cai T, Zhang Y, Ho YL, Link N, Sun J, Huang J, Cai TA, Damrauer S, Ahuja Y, Honerlaw J, Huang J, Costa L, Schubert P, Hong C, Gagnon D, Sun YV, Gaziano JM, Wilson P, Cho K, Tsao P, O’Donnell CJ, Liao KP; VA Million Veteran Program. Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study. JAMA Cardiol, 2018; 3: 849-857

52) Rao AS, Lindholm D, Rivas MA, Knowles JW, Montgomery SB, Ingelsson E. Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke. Circ Genom Precis Med, 2018; 11: e002162

53) Trinder M, DeCastro ML, Azizi H, Cermakova L, Jackson LM, Frohlich J, et al. Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. J Am Coll Cardiol, 2020; 75: 2682-2693